作者
Sean Wharton, Peter Yin, Melonie Burrows, Errol Gould, Jessica Blavignac, Rebecca AG Christensen, Elham Kamran, Fernando Camacho, Maxime Barakat
发表日期
2021/8
期刊
International Journal of Obesity
卷号
45
期号
8
页码范围
1687-1695
出版商
Nature Publishing Group
简介
Background
Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents.
Methods
This was a post-hoc analysis of NB vs. placebo (PL) among subjects with type 2 diabetes stable on an incretin agent prior to randomization in a double-blind, PL-controlled cardiovascular outcome trial (N = 1317).
Results
Over 1 year, mean weight loss was significantly greater among NB patients vs. PL among those taking DPP-4i (mean absolute difference 4.6% [p < 0.0001]) and those taking GLP-1RAs (mean absolute difference 5.2%, p < 0.0001). Proportions of subjects achieving 5% weight loss were significantly greater for NB vs. PL at weeks 26 and 52 among those taking DPP-4is or GLP-1RAs …
学术搜索中的文章
S Wharton, P Yin, M Burrows, E Gould, J Blavignac… - International Journal of Obesity, 2021